Sarepta Surprised By CRL For Exon 53-Skipping DMD Drug Golodirsen

 
• By Mandy Jackson
  
Accept - Refuse_529502731_1200.jpg
US FDA approval never is certain, but golodirsen's rejection was surprising. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip